BioLine RX Stock

BioLine RX Revenue CAGR 5Y

Delisted

Revenue CAGR (5 Year) of BioLine RX (BLRX.TA) as of Aug 4, 2026.

Revenue CAGR 5Y

0.00

Last updated:

Revenue CAGR (5 Year) of BioLine RX is 2026 0.00 . Revenue CAGR (5 Year) of BioLine RX was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLine RX stock

On Eulerpool you can find the complete historical development of Revenue CAGR (5 Year) BioLine RX since 2006 – with annual values, charts, and detailed analysis.

The 5-year revenue CAGR shows the compound annual growth rate of revenue over the past five years.

To evaluate Revenue CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Revenue CAGR (5 Year).

Revenue CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue CAGR (5 Year)'s BioLine RX historically and in real time.

Access this data via the Eulerpool API

Growth — BioLine RX

All Key Metrics — BioLine RX